

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Reid, Stewart E.	POSITION TITLE Research Associate Professor of Medicine, University of North Carolina at Chapel Hill (UNC) Faculty Advisor, Centre for Infectious Disease Research in Zambia (CIDRZ)		
eRA COMMONS USER NAME (credential, e.g., agency login) STEWARTREID			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
University of Guelph, Guelph, Canada	BSc	1978	Environmental Biology
McMaster University, Hamilton, Canada	MD	1984	Medicine
University of British Columbia, Vancouver, Canada	FRCP(C)	1990	Internal Medicine
Diploma American Board of Internal Medicine	ABIM	1990	Internal Medicine
Gorgas Institute of Trop. Med., Lima, Peru	Diploma	2001	Tropical Medicine
University of Alabama at Birmingham	MPH	2002	International Health

**A. Personal Statement**

I am Research Associate Professor of Medicine in the Division of Infectious Disease at the University of North Carolina-Chapel Hill and have lived in Zambia since 2002. At present, I serve as Senior Faculty Advisor for the Centre for Infectious Disease Research in Zambia (CIDRZ) Tuberculosis Unit and Senior Faculty Mentor and Co-PI on ACTG 5288, 5274 and 5279. I am also HPTN Site PI and Clinical Research Site Leader for the Matero Ref Health Centre which included the successful implementation of HPTN 039 (including 3 sub-studies) and currently the implementation of HPTN 063: Preparing for International Prevention Trials. My research interests include combination HIV prevention, the diagnosis and treatment of tuberculosis in HIV-infected patients and vulnerable populations, and operations research related to provision of health care in resource limited settings.

From 2003 to 2012 I was CIDRZ Medical Director and contributed leadership towards the rapid and extensive scale-up of the country-wide antiretroviral treatment (ART) program which became one of the most successful programs in the developing world and that eventually put over 200,000 patients on treatment. At present I also fulfill the role of Laboratory Medical Director for the CIDRZ Central Lab – a state-of-the-art research lab - which provides quality lab services to our network and non-network research programs as well as service programs.

From 2006 to 2012 I was Head of the CIDRZ Tuberculosis (TB) Research Unit and spearheaded both National Institutes of Health network funded, and non-network funded TB research, leading a team of 65 full-time Zambian staff and five full-time expatriate staff dedicated to TB research and service operations. The extensive portfolio of work conducted by the TB department is supported through funding received from numerous competitive grant processes from multiple agencies including: NIH, WHO, CDC, CFAR (NIH), CRDF (NIAID), and PEPFAR and represents more than 12 million dollars over the last 6 years. With ten years of in-country experience, I have substantial understanding of operations and clinical research of both HIV and TB in Zambia.

**B. Positions and Honors****Professional Experience**

1984-1985	Rotating Internship, St. Paul's Hospital, Vancouver, Canada
1990-2000	Consultant Internal Medicine, Nelson Regional Hospital, Nelson, Canada
2000	Consultant, Internal Medicine, Nanaimo Regional General Hospital, Nanaimo, Canada
2001-2002	Graduate Assistant, Sparkman Center for International Public Health Education, UAB
2002-2005	Research Assistant Professor of Medicine, UAB and CIDRZ
2004-Present	Medical Director, CIDRZ, Lusaka, Zambia
2006-2008	Assistant Professor of Medicine, Dept. of Medicine, Division of Infectious Disease, UAB
2008- 2012	Associate Professor of Medicine, Dept. of Medicine, Division of Infectious Disease, UAB
2012-Present	Research Associate Professor of Medicine, Dept. of Medicine, Division of ID, UNC

**Awards:**

- 2010 Research Excellence Award, Department of Medicine, University of Alabama  
 2009 Research Excellence Award, Department of Medicine, University of Alabama  
 2007 Finalist, Charles C. Shepard Science Award, US Centers for Disease Control and Prevention  
 2007 James H. Nakano Citation, Coordinating Center for Infectious Disease, US CDC

**Other Experience and Professional Memberships**

- 1985 Medical Council of Canada  
 1985 College of Physicians and Surgeons of British Columbia  
 1985 State of Washington Federal Licensing Exam  
 1989 Fellow, Royal College of Physicians and Surgeons of Canada  
 1989 Diplomate, American Board of Internal Medicine  
 2004 Advisor, World Health Organization, Integrated Management of Adult Illness  
 2006 Advisor, World Health Organization, Consultation on the Essential Interventions for Integrated HIV Prevention, Treatment, Care and Support  
 2008 Advisory Board, Tibotec, Development of a Medical Strategy for DRV/R, TMC 125 and TMC 278 in sub-Saharan Africa, Dar es Salaam, Tanzania  
 2008 Advisor, Foundation for Innovative New diagnostics (FIND), Geneva, Switzerland  
 2008 Advisor, World Health Organization, Advisor, Consultation to update guidelines for the management of STIs, Dept. of Reproductive Health and Research  
 2009 Advisor, World Health Organization, Consultation: Manual for District Hospital Care for Integrated Management of Adult Illness (IMAI) in Resource Limited Settings, Addis Ababa, Ethiopia,  
 2010 Advisor, World Health Organization, Guidelines Meeting on Preventive Therapy and Case Finding for Tuberculosis in People Living with HIV. 25-27 January 2010, Geneva Switzerland  
 2010 Expert Guideline Panel, World Health Organization, Integrated Management of Adult & Adolescent Illness (IMAI) District Clinician Manual: Hospital Care for Adolescents and Adults, Treatment Recommendations for Opportunistic Infections, 26-29 October, Geneva, Switzerland  
 2011 External Reviewer, World Health Organization/Bill and Melinda Gates Foundation, African Comprehensive HIV/AIDS Partnerships (ACHAP) Tuberculosis/HIV Support to Botswana Ministry of Health, May 9-13.  
 2011 Expert Advisory Panel, World Health Organization, HIV Drug Resistance ResNet, 14 - 15 February.

**C. Selected peer-reviewed publications (15 of 37 published or in press)**

1. **Reid SE**, Reid CA, Vermund SH. Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy. *Int J STD AIDS*. 2004 Nov;15(11):713-6. Review. PMID: 15537453.
2. **Reid SE**, Mulenga LB, Folk WR, Tambatamba BC, Chi BH. Abandonment of antiretroviral therapy: a potential barrier to scale-up in sub-Saharan Africa. *S Afr Med J*. 2008 Jun;98(6):448, 450. PMID: PMC3437649.
3. Celum C, Wald A, Hughes J, Sanchez J, **Reid S**, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwierski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008 Jun 21;371(9630):2109-19. PMID: PMC2650104.
4. Harris JB, Hatwiinda SM, Randels KM, Chi BH, Kancheya NG, Jham MA, Samungole KV, Tambatamba BC, Cantrell RA, Levy JW, Kimerling ME, **Reid SE**. Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia. *Int J Tuberc Lung Dis*. 2008 Jul;12(7):773-9. PMID: 18544203.
5. **Reid SE**, Dai JY, Wang J, Sicalwe BN, Akpomiemie G, Cowan FM, Delany-Moretlwe S, Baeten JM, Hughes JP, Wald A, Celum C. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. *J Acquir Immune Defic Syndr*. 2010 Apr;53(5):606-13. PMID: PMC2845724.
6. Fuchs J, Celum C, Wang J, Hughes J, Sanchez J, Cowan F, **Reid S**, Delany-Moretlwe S, Corey L, Wald A; HIV Prevention Trials Network 039 Protocol Team. Clinical and virologic efficacy of herpes simplex virus

- type 2 suppression by acyclovir in a multicontinent clinical trial. *J Infect Dis*. 2010 Apr 15;201(8):1164-8. PMID: PMC2856478.
7. Kim HN, Wang J, Hughes J, Coombs R, Sanchez J, **Reid S**, Delany-Moretlwe S, Cowan F, Fuchs J, Eshleman SH, Khaki L, McMahon MA, Siliciano RF, Wald A, Celum C. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. *J Infect Dis*. 2010 Sep 1;202(5):734-8. PMID: PMC2964878.
  8. Topp SM, Chipukuma JM, Chiko MM, Wamulume CS, Bolton-Moore C, **Reid SE**. Opt-out provider-initiated HIV testing and counselling in primary care outpatient clinics in Zambia. *Bull World Health Organ*. 2011 May 1;89(5):328-335A. Epub 2011 Mar 31. PMID: PMC3089388.
  9. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, **Reid S**, Hakim J, Mohapi L, Mugenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med*. 2011 Oct 20;365(16):1482-91. PMID: PMC3327101.
  10. Turnbull ER, Kancheya NG, Harris JB, Topp SM, Henostroza G, **Reid SE**. A Model of Tuberculosis Screening for Pregnant Women in Resource-Limited Settings Using Xpert MTB/RIF. *J Pregnancy*. 2012;2012:565049. Epub 2011 Oct 5. PMID: PMC3189576.
  11. Turnbull ER, Kaunda K, Harris JB, Kapata N, Muvwimi MW, Kruuner A, Henostroza G, **Reid SE**. An evaluation of the performance and acceptability of three LED fluorescent microscopes in Zambia: lessons learnt for scale-up. *PLoS One*. 2011;6(11):e27125. Epub 2011 Nov 4. PMID: PMC3208552.
  12. Baeten JM, **Reid SE**, Delany-Moretlwe S, Hughes JP, Wang RS, Wilcox E, Limbada M, Akpomiemie G, Corey L, Wald A, Celum C. Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. *Sex Transm Dis*. 2012 Jan;39(1):21-4. PMID: PMC3244838.
  13. Lu Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, **Reid SE**, Hughes JP, Wilcox E, Corey L, Hendrix CW. Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. *Antimicrob Agents Chemother*. 2012 May;56(5):2777-9. Epub 2012 Feb 13. PMID: PMC3346629.
  14. **Reid SE**, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, Roberts ST, Krüüner A, Morse JC, Kapata N, Chisela C, Henostroza G. Tuberculosis and HIV control in sub-Saharan African prisons: "thinking outside the prison cell". *J Infect Dis*. 2012 May 15;205 Suppl 2:S265-73. Epub 2012 Mar 22. PMID: 22448015.
  15. Topp SM, Li MS, Chipukuma JM, Chiko MM, Matongo E, Bolton-Moore C, **Reid SE**. Does provider-initiated counselling and testing (PITC) strengthen early diagnosis and treatment initiation? Results from an analysis of an urban cohort of HIV-positive patients in Lusaka, Zambia. *J Int AIDS Soc*. 2012 Sep 24;15(2):17352. PMID: PMC3494161.

## D. Research Support

### Ongoing Support

5 U2G GH000226-02  
CDC

Chintu (PI)

09/30/11 – 9/29/16

HIV Integrated Local Ownership Project (HILO)

The predecessor to this PEPFAR grant enabled CIDRZ to develop a comprehensive HIV/AIDS prevention, care, and treatment program in Zambia. Included in this parent grant is funding for "3I's" implementation which includes intensified tuberculosis case finding in rural Zambia using Xpert MTB/RIF in Zambian prisons and HIV clinics as well as another study of enhanced tuberculosis screening in HIV clinic patients to determine the prevalence and incidence. Role: Investigator

U2G PS001421-01  
CDC

Chi (PI)

01/01/09– 03/31/14

Expansion of ART, Tuberculosis, and VCT programs in Zambia

The goal of this project is to expand ART, Tuberculosis and VCT in the rural Zambia districts. This program is providing technical support for Tuberculosis HIV integration services in Western, Southern and Lusaka

Province and strengthening the quality of programs already implemented, renovating infrastructure and improving tuberculosis diagnostics within MOH facilities. Role: Investigator

7 UM1 AI069455-06 Stringer (PI) 05/10/07 – 11/30/13  
NIH/NIAID

Centre for Infectious Disease Research in Zambia, HIV/AIDS Clinical Trials Unit

This is a U-01 grant from NIH/NIAID that supports our integrated clinical trials unit at CIDRZ. We affiliate with 4 DAIDS-sponsored networks through this grant: the AIDS Clinical Trials Group, the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, the Microbicides Trials Network, and the HIV Prevention Trials Network. Role: Investigator

966/0800.0168/AI068619 Stringer (PI) 06/01/09 – 05/31/13  
NIH/FHI

HIV Prevention Trials Network (HPTN) 063: Positive Prevention

The aim of this project is to conduct preparatory research needed to design a behavioral intervention to decrease sexual transmission risk behaviors in HIV-infected individuals in care. Role: Principal Investigator

GH11-005 Kancheya (PI) 07/01/12 - 06/30/13  
Center for Disease Control and Prevention (CDC)

The major goal of this project is to optimizing clinical outcomes in HIV-infected adult and pediatric patients using Xpert MTB/RIF in a semi-rural setting in Zambia. Role: Investigator

### **Completed Support**

T9-370-114ZAM Reid (PI) 08/01/10 – 03/01/12

World Health Organization, Stop TB/TB REACH, Introducing Routine Tuberculosis Screening in Zambian Prisons. The primary aim is implement Tuberculosis screening, HIV testing and referral to care in Zambian Prisons. Role: Co-PI

CA-05-9-300-01375-5-00 Stringer (PI) 03/01/09 – 09/30/10

Elizabeth Glaser Pediatric AIDS Foundation, Help Expand Antiretroviral Therapy for Children and Families  
The primary aim of this grant is to expand access to HIV care and antiretroviral treatment to HIV infected individuals in Zambia. Role: Medical Director; Program Director

American Board of Internal Medicine Reid (PI) 10/01/07 - 06/30/10

Using Performance Assessment Product in the International Setting

The purpose of this study is to determine if the ABIM's HIV Practice Improvement Module can be of use in international settings. Role: PI

U62/CCU622410-04 Stringer (PI) 04/01/06 – 03/31/10

US CDC/Tulane University, University Technical Assistance in Support of the Global AIDS Program

Contract through Tulane University to support continued antiretroviral therapy expansion in Zambia to establish tuberculosis culture capability at the CIDRZ lab in Lusaka, and to perform MDR tuberculosis surveillance. Role: Program Director

5U01 AI52054-06 Reid (PI) 07/01/02 – 3/31/10

Passthrough from the University of Washington/NIH/NIAID, HPTN 039: Acyclovir to Prevent HIV Acquisition in HSV-2+ Persons. The aim of this project is to determine the efficacy of twice daily acyclovir in preventing HIV infection among high risk HIV-negative, HSV-2 positive women and men who have sex with men (WSM, MSM). Role: Principal Investigator